Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B

Moderna, Inc.

2024-Q1 EPS reported -$3.07 revenue$167,000,000

GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.
Spikevax product sales fell 91% YoY to $167M; $100M U.S., $67M international.
Reaffirms 2024 product sales ~$4B; expects ~$0.3B net sales in H1 2024.
Cash and investments $12.2B at March 31, down from $13.3B at year-end 2023.
RSV vaccine launch targeted for fall 2024; flu vaccine filing expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moderna, Inc. reported the first quarter ended March 31, 2024 results: revenue $167 million, net income GAAP net loss of $1.2 billion, EPS GAAP diluted EPS of $(3.07). Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $167 million
Net income: GAAP net loss of $1.2 billion
EPS: GAAP diluted EPS of $(3.07)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million , GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-24-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.